2023
Using dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis
Fleming L, Lemonde A, Benrimoh D, Gold J, Taylor J, Malla A, Joober R, Iyer S, Lepage M, Shah J, Corlett P. Using dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis. Scientific Reports 2023, 13: 4841. PMID: 36964175, PMCID: PMC10039017, DOI: 10.1038/s41598-023-31909-w.Peer-Reviewed Original ResearchConceptsHallucinations/delusionsFirst-episode psychosisFirst-episode psychosis participantsEarly intervention programsPathophysiological mechanismsUnderlying pathophysiologyEpisode psychosisPsychotic illnessPsychotic symptomsPsychotic disordersSchizoaffective disorderAuditory hallucinationsPositive symptomsHallucination severityNegative symptomsSymptomsDisorganization symptomsIntervention programsHallucinationsIllnessPsychosis participantsPsychosisDelusionsDisordersParticipants
2000
Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action
Jentsch J, Roth R, Taylor J. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Progress In Brain Research 2000, 126: 433-453. PMID: 11105661, DOI: 10.1016/s0079-6123(00)26028-7.Peer-Reviewed Original ResearchMeSH KeywordsAmphetaminesAmygdalaAnimalsBehaviorBrain MappingCentral Nervous System StimulantsCognitionCorpus StriatumDepressionDopamineDopamine AgonistsEmotionsHaplorhiniHumansLearningLimbic SystemMammalsMemoryMental DisordersNeural PathwaysNeurotransmitter AgentsNucleus AccumbensPhencyclidinePrefrontal CortexPsychotropic DrugsReceptors, NeurotransmitterRewardSchizophreniaSubstance-Related DisordersConceptsForebrain sitesPsychotropic drug actionPrecise anatomical sitesRole of dopamineDopaminergic dysfunctionDopaminergic transmissionDopaminergic functionDopamine neuronsDopaminergic responseReward-related stimuliCorticolimbic circuitsChronic activationDopaminergic activationStriatal regionsAfferent controlAnatomical sitesCorticostriatal systemMental disordersNeuropsychiatric disordersNeuromodulatory systemsPersistent neuroadaptationsDrug actionBehavioral functionsCellular mechanismsDopamine
1998
Subchronic Phencyclidine Administration Increases Mesolimbic Dopaminergic System Responsivity and Augments Stress- and Psychostimulant-Induced Hyperlocomotion
Jentsch J, Taylor J, Roth R. Subchronic Phencyclidine Administration Increases Mesolimbic Dopaminergic System Responsivity and Augments Stress- and Psychostimulant-Induced Hyperlocomotion. Neuropsychopharmacology 1998, 19: 105-113. PMID: 9629564, DOI: 10.1016/s0893-133x(98)00004-9.Peer-Reviewed Original ResearchMeSH Keywords3,4-Dihydroxyphenylacetic AcidAnalysis of VarianceAnimalsBrainDextroamphetamineDisease Models, AnimalDizocilpine MaleateDopamineDrug Administration ScheduleHaloperidolLimbic SystemMaleMotor ActivityPhencyclidinePrefrontal CortexRatsRats, Sprague-DawleySchizophreniaStress, PsychologicalTime FactorsConceptsDopamine utilizationHaloperidol-induced increasePCP exposureFrontal cortical dysfunctionAmphetamine-induced hyperlocomotionSubchronic PCP administrationMesolimbic dopamine transmissionPCP-treated ratsCortical dopaminergicCortical dysfunctionDopaminergic deficitDopaminergic transmissionDopaminergic functionDopamine transmissionDopaminergic hypoactivityPCP administrationBehavioral pathologyCognitive deficitsRatsSystem responsivityHyperlocomotionDopaminergicExposureCurrent studyDeficits
1997
Enduring Cognitive Deficits and Cortical Dopamine Dysfunction in Monkeys After Long-Term Administration of Phencyclidine
Jentsch J, Redmond D, Elsworth J, Taylor J, Youngren K, Roth R. Enduring Cognitive Deficits and Cortical Dopamine Dysfunction in Monkeys After Long-Term Administration of Phencyclidine. Science 1997, 277: 953-955. PMID: 9252326, DOI: 10.1126/science.277.5328.953.Peer-Reviewed Original ResearchConceptsDopamine utilizationPrefrontal cortexAtypical antipsychotic drug clozapineLong-term administrationDirect drug effectAntipsychotic drug clozapinePsychotomimetic drug phencyclidineAdministration of phencyclidineDorsolateral prefrontal cortexDopamine hypofunctionPrefrontal cortex functionCognitive dysfunctionPhencyclidine treatmentBehavioral deficitsDopamine dysfunctionPsychiatric disordersDrug effectsDrug clozapineDrug phencyclidineBrain regionsCognitive deficitsCortex functionCognitive functionPhencyclidineCortexDysregulation of Mesoprefrontal Dopamine Neurons Induced by Acute and Repeated Phencyclidine Administration in the Nonhuman Primate: Implications for Schizophrenia
Jentsch J, Elsworth J, Taylor J, Redmond D, Roth R. Dysregulation of Mesoprefrontal Dopamine Neurons Induced by Acute and Repeated Phencyclidine Administration in the Nonhuman Primate: Implications for Schizophrenia. Advances In Pharmacology 1997, 42: 810-814. PMID: 9328021, DOI: 10.1016/s1054-3589(08)60870-4.Peer-Reviewed Original ResearchConceptsPCP administrationAcute PCP administrationNegative symptomsDA systemMesoprefrontal dopamine neuronsSubcortical DA systemsBrains of patientsSchizophrenia-like symptomatologyDevelopment of neuropathologyDistinct behavioral effectsDAergic dysfunctionDA metabolismDAergic functionDopamine neuronsCognitive dysfunctionNovel agentsDeficits of schizophreniaFrontal cortexPsychotomimetic propertiesNeurobiological effectsDopamine systemPositive symptomsPhencyclidine administrationBehavioral effectsAdministration